undamentalytics Newsletter
Sign in

Abvc Biopharma, Inc. cash flow statement

In fiscal 2025, Abvc Biopharma, Inc.'s operations generated −$3.0m of cash; it spent $0 on capital projects, leaving free cash flow of −$3.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Sept 20102011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Dec 20152018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash from operations−1−2−1−00—−1−3−5−8−7−4−2−3
Depreciation and amortisation0000——00000000
Stock-based pay——————00457034
Capital spending−0000—————00000
Free cash flow−1−2−1−0—————−8−8−4−2−3
Free cash flow after stock pay—————————−13−15−4−5−7
Shares issued———————181141——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ABVC vs CRDFABVC vs CRVOABVC vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Abvc Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abvc Biopharma, Inc.